Contact the Editorial Desk

Correspondence

Assent Peptides is glad to hear about the research record: a citation quoted inaccurately, a regulatory reference gone out of date, or a peer-reviewed study on retatrutide or tirzepatide that should join the references page. Corrections that improve accuracy are the most useful mail the casebook receives, and each is read with care.

The notes easiest to act on name: the page in question, the exact passage at issue, and the supporting citation — a DOI or PubMed ID wherever possible. That lets a proposed change be checked against its source directly.

Editorial mailbox: editors@assentpeptides.com

Beyond the casebook

A few things sit outside what the site can take up — flagged so no message waits on an answer it will never get. Assent Peptides keeps a casebook of literature, not a clinic or a storefront, so it cannot:

• Advise on, endorse, or comment on human use of any compound covered here.
• Name a dose, schedule, or route for any individual.
• Diagnose a condition or judge whether a finding fits a specific person.
• Sell, source, recommend, or help you locate any compound from any supplier.
• Field anti-doping questions from athletes about compound use.

Anyone seeking medical guidance should consult a licensed clinician in their own jurisdiction. Replies to correspondence are not guaranteed; the mailbox is checked intermittently.